APA (7th ed.) Citation

W, P., CA, O., JF, C., M, H., Z, T., C, S., . . . EM, O. (2026). Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: The phase 2 POLAR trial. Nature medicine, 32(5), 1783. https://doi.org/10.1038/s41591-026-04299-5

Chicago Style (17th ed.) Citation

W, Park, et al. "Pembrolizumab and Olaparib in Homologous-recombination-deficient Metastatic Pancreatic Cancer: The Phase 2 POLAR Trial." Nature Medicine 32, no. 5 (2026): 1783. https://doi.org/10.1038/s41591-026-04299-5.

MLA (9th ed.) Citation

W, Park, et al. "Pembrolizumab and Olaparib in Homologous-recombination-deficient Metastatic Pancreatic Cancer: The Phase 2 POLAR Trial." Nature Medicine, vol. 32, no. 5, 2026, p. 1783, https://doi.org/10.1038/s41591-026-04299-5.